AbCellera Q4 revenue beats expectations

AbCellera Biologics

24/02/2026 21:21

Overview

Biotech firm's Q4 revenue beat analyst expectations

Net loss for FY 2025 narrowed compared to previous year

Company advanced multiple programs into clinical trials

Outlook

Company plans to advance clinical programs and expand pipeline in 2026

Result Drivers

REVENUE GROWTH - Total FY 2025 revenue increased to $75.1 mln

PIPELINE ADVANCEMENTS - Advanced ABCL635 and ABCL575 into clinical trials in the year, signaling pipeline progress

Company press release: ID:nBw1LlbKsa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$44.90 mln
$6.06 mln (4 Analysts)
Q4 Net Income
-$8.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Abcellera Biologics Inc is $9.50, about 213.5% above its February 23 closing price of $3.03

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)